Current round

Why invest now?

Medium term
Vision

UbitelCare is located in a turning pointWith the technology developed and clinical validation underway, the priority is no longer the product itself, but rather consolidating its deployment in real-world settings, strengthening the solutions ecosystem, and building a network of distribution partners. The current funding round is aimed at accelerating this transition, from a validated product to its widespread adoption.

What stage is the company at?

Ubitelcare enters this round with a developed product, a first commercial version available since July 2024, validation with real patients in the Virgen Macarena University HospitalThere is a technological base with registered intellectual property.

The current bottleneck is not the product itself: it's the extended clinical validation and regulatory certification needed to scale up commercial deployment in the public and private healthcare systems. This funding round is aimed at eliminate that bottleneckI have already implemented the market entry strategy with the appropriate resources.

The company is backed by Google for Startups, which has provided cloud services and infrastructure worth $25,000 as part of its program to support technology startups. The application to ENISA is pending processing.

DESTINATION OF FUNDS

What is the investment used for?

The allocation of funds follows a logical sequence: consolidate clinical evidence, complete the certification that opens the European market, mature the product for its commercial deployment and provide the company with the structure to scale. These are not isolated items, but linked steps towards commercialization, and each one reduces the risk of the next one being executed.

Extended clinical validation

Extension of the study to the Virgen Macarena University Hospital and new validation settings. Clinical evidence is key for institutional adoption and certification.

Regulatory advantage

Ubicardio certification as Software as a Medical Device (SaMD) Class IIa in accordance with the MDR, with Notified Body and ISO 13485: the requirement to access the European clinical market.

Product development

Evolution of the platform for commercial deployment: new data sources and consolidation of the Care ecosystem.

Diversified model

Resources for the execution of the business plan: sales team, management of strategic alliances with distribution partners and operations necessary to support growth.

The next phase: from control to anticipation

Medium term
Vision

UbitelCare is developing in parallel a next generation predictive system, capable of anticipating adverse cardiovascular events using AI and massive time series analysis.

Their models are trained using the database generated by the current preventative system, so investing today builds that asset. It opens up a larger market opportunity, with higher barriers to entry and difficult to replicate.

What you will find in the dossier

Business model

Executive summary and market

Founding team

Track record of the team

Milestones and traction

Progress, achievements and support